AIIL - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | AIIL | Market Cap | 42,695 Cr. | Current Price | 503 ₹ | High / Low | 684 ₹ |
| Stock P/E | 10.6 | Book Value | 191 ₹ | Dividend Yield | 0.04 % | ROCE | 30.8 % |
| ROE | 34.1 % | Face Value | 1.00 ₹ | DMA 50 | 565 ₹ | DMA 200 | 530 ₹ |
| Chg in FII Hold | 0.37 % | Chg in DII Hold | -0.07 % | PAT Qtr | 765 Cr. | PAT Prev Qtr | 941 Cr. |
| RSI | 37.6 | MACD | -23.2 | Volume | 2,13,390 | Avg Vol 1Wk | 3,28,170 |
| Low price | 265 ₹ | High price | 684 ₹ | PEG Ratio | 0.12 | Debt to equity | 0.17 |
| 52w Index | 56.8 % | Qtr Profit Var | -9.38 % | EPS | 47.3 ₹ | Industry PE | 18.9 |
📊 AIIL (₹503) and AUROPHARMA (₹1,209) show different swing trade setups. AIIL trades below its 50 DMA (₹565) and 200 DMA (₹530), with RSI at 37.6 indicating oversold conditions and MACD negative (-23.2), suggesting short-term weakness but potential rebound. Fundamentals are strong with low P/E (10.6 vs industry 18.9), high ROCE (30.8%), and ROE (34.1%), though recent profit decline is a concern. AUROPHARMA trades above both DMAs with neutral RSI (56.9) and slightly positive MACD (0.83), showing stable momentum. Valuations are higher (P/E 34.7 vs industry 29.1), but earnings growth supports the premium.
💡 Optimal Entry Price:
- AIIL: ₹480–₹490 (oversold zone, near support).
- AUROPHARMA: ₹1,170–₹1,190 (near DMA support).
💡 Exit Strategy:
- AIIL: Exit near ₹540–₹560 if rebound occurs.
- AUROPHARMA: Exit near ₹1,260–₹1,280 unless trend strengthens further.
✅ Positive
- AIIL: Strong ROCE (30.8%) and ROE (34.1%), attractive P/E (10.6), PEG ratio 0.12 indicates undervaluation.
- AUROPHARMA: Consistent profit growth (PAT ₹581 Cr. vs ₹559 Cr.), EPS ₹34.8, stable technicals above DMAs.
⚠️ Limitation
- AIIL: RSI oversold, MACD negative, quarterly PAT decline (₹765 Cr. vs ₹941 Cr.), low dividend yield (0.04%).
- AUROPHARMA: High PEG ratio (8.14), moderate ROCE (10.8%) and ROE (8.65%), FII holding reduced (-0.26%).
📉 Company Negative News
- AIIL: Profit decline in recent quarter raises caution.
- AUROPHARMA: Valuation premium compared to industry peers.
📈 Company Positive News
- AIIL: Strong fundamentals, attractive valuation, potential rebound from oversold levels.
- AUROPHARMA: Stable earnings growth, resilient demand in pharma sector.
🏭 Industry
- AIIL: Industry PE ~18.9, company trades at discount, offering value opportunity.
- AUROPHARMA: Industry PE ~29.1, company trades at premium supported by growth expectations.
🔎 Conclusion
AIIL is undervalued with strong fundamentals but currently weak technicals, making it a candidate for rebound swing trades near ₹480–₹490 with exit around ₹540–₹560. AUROPHARMA is technically stable and offers moderate upside, suitable for entry near ₹1,170–₹1,190 and exit near ₹1,260–₹1,280. AIIL is better for value-driven swing traders, while AUROPHARMA suits momentum